ISB News

Cancer Genomics Cloud: ISB and Google Featured in MIT Tech Review

ISB Recieves $6.5M NIH Contract to Create Cancer Genomics Cloud with Google and SRA International (Image credit: MIT Tech Review)

(Above illustration from MIT Technology Review.)

MIT Technology Review published an article about the launch of Google Genomics and included a mention of ISB’s new Cancer Genomics Cloud project. ISB received an up-to $6.5 million, two-year NIH contract in collaboration with Google and SRA International.

From the MIT Technology Review article:

The idea is to create “cancer genome clouds” where scientists can share information and quickly run virtual experiments as easily as a Web search, says Sheila Reynolds, a research scientist at the Institute for Systems Biology in Seattle. “Not everyone has the ability to download a petabyte of data, or has the computing power to work on it,” she says.

This article also was cited in The Scientist here.

Researchers interested in participating in the Cancer Genomics Cloud project, please visit cgc.isbscience.net.

Read more about ISB’s Cancer Genomics Cloud project:

cancerGenomicsCloud

 

Recent Articles

  • 2024 Year in Review

    Reflecting on the past year, ISB has a lot to celebrate: groundbreaking research published in leading scientific journals, well-earned promotions, widespread media coverage, and more. Enjoy our year-in-review roundup highlighting some of the important, interesting, and impactful highlights of 2024.

  • My Digital Gut

    ISB Named Winner of 2024-2025 Amazon Web Services IMAGINE Grant for Nonprofits

    ISB has been selected as a winner of the 2024 Amazon Web Services (AWS) IMAGINE Grant. The grant will support ISB’s continued development of My Digital Gut, an online decision-support platform that will help make microbiome-informed nutrition and healthcare personalized, predictive, and preventive. 

  • ISB-Developed MetaboCore Offers Precision Cancer Care Faster Than Ever 

    ISB Associate Professor Dr. Wei Wei and his colleagues have developed a promising new companion diagnostic tool called MetaboCore to help physicians quickly select the most effective systemic therapy for each cancer patient.